$DNTH
Dianthus Therapeutics, Inc. /DE/

2023 Q3 Form 10-Q Financial Statement

#000095017023037605 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $924.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.720M $5.318M
YoY Change 44.08% -17.93%
% of Gross Profit
Research & Development $7.960M $139.0K
YoY Change -28.93% -98.8%
% of Gross Profit
Depreciation & Amortization $19.00K $0.00
YoY Change -95.97% -100.0%
% of Gross Profit
Operating Expenses $16.68M $7.375M
YoY Change -3.3% -59.22%
Operating Profit -$15.76M -$7.375M
YoY Change -8.66% -59.22%
Interest Expense $1.010M $4.091M
YoY Change -15.13% 403.82%
% of Operating Profit
Other Income/Expense, Net $996.0K $636.0K
YoY Change 111.91%
Pretax Income -$14.76M -$3.284M
YoY Change -8.11% -80.99%
Income Tax
% Of Pretax Income
Net Earnings -$14.76M -$3.284M
YoY Change -8.09% -80.99%
Net Earnings / Revenue -1597.73%
Basic Earnings Per Share -$3.78 -$0.05
Diluted Earnings Per Share -$3.78 -$0.05
COMMON SHARES
Basic Shares Outstanding 60.66M 60.65M
Diluted Shares Outstanding 3.907M 60.65M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $189.9M $77.59M
YoY Change 48.03% -44.35%
Cash & Equivalents $157.3M $62.63M
Short-Term Investments $32.60M $14.96M
Other Short-Term Assets $800.0K $1.045M
YoY Change -79.02% -60.07%
Inventory
Prepaid Expenses
Receivables $232.0K
Other Receivables $0.00
Total Short-Term Assets $191.5M $78.64M
YoY Change 44.93% -44.64%
LONG-TERM ASSETS
Property, Plant & Equipment $195.0K $0.00
YoY Change -96.91% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $0.00
YoY Change -94.38% -100.0%
Total Long-Term Assets $1.009M $0.00
YoY Change -96.85% -100.0%
TOTAL ASSETS
Total Short-Term Assets $191.5M $78.64M
Total Long-Term Assets $1.009M $0.00
Total Assets $192.5M $78.64M
YoY Change 17.27% -55.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.369M $813.0K
YoY Change -46.9% -60.28%
Accrued Expenses $11.20M $3.221M
YoY Change 66.57% -44.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.08M $4.034M
YoY Change 1.22% -64.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.000M $0.00
YoY Change -96.32% -100.0%
Total Long-Term Liabilities $1.000M $0.00
YoY Change -96.32% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.08M $4.034M
Total Long-Term Liabilities $1.000M $0.00
Total Liabilities $14.08M $4.034M
YoY Change -64.88% -89.77%
SHAREHOLDERS EQUITY
Retained Earnings -$78.90M -$434.5M
YoY Change -79.34% 18.78%
Common Stock $257.2M $509.1M
YoY Change -49.2% 1.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $178.4M $74.60M
YoY Change
Total Liabilities & Shareholders Equity $192.5M $78.64M
YoY Change 17.27% -55.1%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$14.76M -$3.284M
YoY Change -8.09% -80.99%
Depreciation, Depletion And Amortization $19.00K $0.00
YoY Change -95.97% -100.0%
Cash From Operating Activities $17.13M -$6.544M
YoY Change -224.06% -61.17%
INVESTING ACTIVITIES
Capital Expenditures -$150.0K $0.00
YoY Change -5.06% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$17.03M $18.87M
YoY Change -210.59%
Cash From Investing Activities -$16.88M $18.87M
YoY Change -210.75% -14731.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 138.4M 0.000
YoY Change 4910.5% -100.0%
NET CHANGE
Cash From Operating Activities 17.13M -6.544M
Cash From Investing Activities -16.88M 18.87M
Cash From Financing Activities 138.4M 0.000
Net Change In Cash 138.7M 12.33M
YoY Change 3205.29% -172.82%
FREE CASH FLOW
Cash From Operating Activities $17.13M -$6.544M
Capital Expenditures -$150.0K $0.00
Free Cash Flow $17.28M -$6.544M
YoY Change -226.59% -60.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001690585
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2015-06-01
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38541
dei Entity Registrant Name
EntityRegistrantName
Magenta Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-0724163
dei Entity Address Address Line1
EntityAddressAddressLine1
300 Technology Square, 8th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
242-0170
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60664697
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62633000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57626000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
14960000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
54415000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1045000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3561000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
78638000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
115602000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1780000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23168000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6095000
CY2023Q2 us-gaap Assets
Assets
78638000
CY2022Q4 us-gaap Assets
Assets
146645000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
813000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2454000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3221000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8271000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3824000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4034000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14549000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26138000
CY2023Q2 us-gaap Liabilities
Liabilities
4034000
CY2022Q4 us-gaap Liabilities
Liabilities
40687000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60652197
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60652197
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60639909
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60639909
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
61000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
61000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
509029000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
508107000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-181000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-434483000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-402029000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
74604000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
105958000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78638000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146645000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
139000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11603000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8134000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28150000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5318000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6480000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11450000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13767000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
1918000
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
19921000
us-gaap Restructuring Charges
RestructuringCharges
0
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
7375000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
18083000
us-gaap Operating Expenses
OperatingExpenses
39505000
us-gaap Operating Expenses
OperatingExpenses
41917000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7375000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18083000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39505000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41917000
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
4091000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
812000
us-gaap Interest And Other Income
InterestAndOtherIncome
7051000
us-gaap Interest And Other Income
InterestAndOtherIncome
1696000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3284000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17271000
us-gaap Net Income Loss
NetIncomeLoss
-32454000
us-gaap Net Income Loss
NetIncomeLoss
-40221000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60650473
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60650473
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58815543
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58815543
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60648076
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60648076
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58807395
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58807395
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3284000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17271000
us-gaap Net Income Loss
NetIncomeLoss
-32454000
us-gaap Net Income Loss
NetIncomeLoss
-40221000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-133000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
178000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-572000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
13000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-133000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
178000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-572000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3271000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17404000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32276000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40793000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
77459000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
416000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3284000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
74604000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
151188000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
49000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1845000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-133000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17271000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
135678000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
105958000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
922000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
178000
us-gaap Net Income Loss
NetIncomeLoss
-32454000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
74604000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
172672000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
49000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3750000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-572000
us-gaap Net Income Loss
NetIncomeLoss
-40221000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
135678000
us-gaap Profit Loss
ProfitLoss
-32454000
us-gaap Profit Loss
ProfitLoss
-40221000
us-gaap Share Based Compensation
ShareBasedCompensation
922000
us-gaap Share Based Compensation
ShareBasedCompensation
3750000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
421000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
988000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3323000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Increase Decrease In Assets Held For Sale
IncreaseDecreaseInAssetsHeldForSale
-270000
us-gaap Increase Decrease In Assets Held For Sale
IncreaseDecreaseInAssetsHeldForSale
0
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
3301000
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0
mgta Noncash Lease Expense
NoncashLeaseExpense
786000
mgta Noncash Lease Expense
NoncashLeaseExpense
1418000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-8059000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
600000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-228000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2516000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1150000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1426000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-993000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5020000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1482000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-15639000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1432000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42143000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36594000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
245000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
156000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2081000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
3301000
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
9767000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
40117000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
50000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45370000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40273000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
49000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3227000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-76818000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59406000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
133430000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62633000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56612000
mgta Decrease In Right Of Use Asset And Operating Lease Liabilities Due To Lease Termination
DecreaseInRightOfUseAssetAndOperatingLeaseLiabilitiesDueToLeaseTermination
14323000
mgta Decrease In Right Of Use Asset And Operating Lease Liabilities Due To Lease Termination
DecreaseInRightOfUseAssetAndOperatingLeaseLiabilitiesDueToLeaseTermination
0
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.84
us-gaap Net Income Loss
NetIncomeLoss
-32500000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-76500000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-434500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5012616
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8870622
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
14963000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
14960000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
54596000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
183000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
54415000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1621000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4162000
CY2023Q2 mgta Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
0
CY2022Q4 mgta Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
3091000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1321000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
654000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
279000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
364000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3221000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8271000
us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.84
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-8100000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-3300000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
300000
CY2023Q2 us-gaap Other Income
OtherIncome
3300000
CY2023Q1 mgta Stockholder Rights Plan Expiration Date
StockholderRightsPlanExpirationDate
2024-03-30
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
416000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1845000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
922000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3750000
CY2023Q1 us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
The Company had a sublease, as amended, for up to approximately 69,000 square feet of office and laboratory space in Cambridge, Massachusetts. The sublease was subject and subordinate to a prime lease between the sublandlord and the prime landlord. The term of the sublease commenced in June 2018 and was set to expire in February 2028
CY2023Q1 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-8100000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
0
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1601000
us-gaap Operating Lease Cost
OperatingLeaseCost
1602000
us-gaap Operating Lease Cost
OperatingLeaseCost
3203000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
4000
us-gaap Variable Lease Cost
VariableLeaseCost
491000
us-gaap Variable Lease Cost
VariableLeaseCost
510000
CY2023Q2 us-gaap Lease Cost
LeaseCost
0
CY2022Q2 us-gaap Lease Cost
LeaseCost
1605000
us-gaap Lease Cost
LeaseCost
2093000
us-gaap Lease Cost
LeaseCost
3713000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1622000
us-gaap Operating Lease Payments
OperatingLeasePayments
16455000
us-gaap Operating Lease Payments
OperatingLeasePayments
3217000
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2022Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000

Files In Submission

Name View Source Status
0000950170-23-037605-index-headers.html Edgar Link pending
0000950170-23-037605-index.html Edgar Link pending
0000950170-23-037605.txt Edgar Link pending
0000950170-23-037605-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mgta-20230630.htm Edgar Link pending
mgta-20230630.xsd Edgar Link pending
mgta-ex31_1.htm Edgar Link pending
mgta-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mgta-20230630_pre.xml Edgar Link unprocessable
mgta-20230630_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mgta-20230630_cal.xml Edgar Link unprocessable
mgta-20230630_lab.xml Edgar Link unprocessable
mgta-20230630_def.xml Edgar Link unprocessable